Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.12.24	Critical Insights From Xencor Analyst Ratings: What You Need To Know (Benzinga)
26.11.24	Xencor to Participate at Upcoming Investor Conferences (Businesswire)
06.11.24	Xencor Reports Third Quarter 2024 Financial Results (Businesswire)
04.11.24	Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease (Businesswire)
10.10.24	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Businesswire)
04.10.24	Xencor Announces Upcoming Change to Board of Directors (Businesswire)
26.09.24	Xencor Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) (Benzinga)
12.09.24	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares (Businesswire)
11.09.24	Xencor Prices Public Offering Of 6.64 Mln Shares At $18/shr (RTTNews)
11.09.24	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Businesswire)
10.09.24	Xencor Announces Proposed Public Offering of Common Stock (Businesswire)
09.09.24	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Businesswire)
06.09.24	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Businesswire)
05.08.24	Xencor Reports Second Quarter 2024 Financial Results (Businesswire)
31.07.24	Decoding 5 Analyst Evaluations For Xencor (Benzinga)
14.06.24	Peeling Back The Layers: Exploring Xencor Through Analyst Insights (Benzinga)
13.06.24	Xencor To Regain Global Rights To Bispecific T-Cell Engager Plamotamab (RTTNews)
13.06.24	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Businesswire)
10.05.24	Decoding 6 Analyst Evaluations For Xencor (Benzinga)
09.05.24	Xencor Reports First Quarter 2024 Financial Results (Businesswire)
16.04.24	Analyst Scoreboard: 6 Ratings For Xencor (Benzinga)
09.04.24	Xencor Appoints Bart Cornelissen As CFO (RTTNews)
09.04.24	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Businesswire)
28.02.24	Xencor to Present at Upcoming Investor Conferences (Businesswire)
28.02.24	Unveiling 4 Analyst Insights On Xencor (Benzinga)
27.02.24	Recap: Xencor Q4 Earnings (Benzinga)
27.02.24	Xencor Reports Fourth Quarter and Full Year 2023 Financial Results (Businesswire)
26.02.24	Earnings Preview: Xencor (Benzinga)
26.02.24	Ausblick: Xencor legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
20.02.24	Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update (Businesswire)
03.01.24	Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Businesswire)
02.01.24	Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy (Businesswire)
21.11.23	Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference (Businesswire)
07.11.23	Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million (Businesswire)
07.11.23	Xencor Reports Third Quarter 2023 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	73.54	1.72 %	K V
ABB	51.66	0.78 %	K V
Alcon	77.62	0.65 %	K V
Sonova Hldg	299.60	0.64 %	K V
CieFinRichemont	128.30	0.51 %	K V
Swiss Life Hldg	686.80	-0.52 %	K V
Zurich Insur Gr	557.00	-0.68 %	K V
Kuehne+Nagel Int	211.80	-0.75 %	K V
Givaudan	3’866.00	-1.07 %	K V
Novartis	91.41	-1.73 %	K V

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten